Archive for 2009

Top 4 Healthcare Predictions for 2010

This is a guest post from Cliff Cramer, Director of the Healthcare and Pharmaceutical Management Program at Columbia Business School. Do you have a response to Cramer’s post? Post them in the comments section below. Multi-national pharmaceutical and medical technology companies will increase their investments in emerging markets, notably China and India, to access cost […]


India, Intellectual Property and Biotechnology Industry

This is a guest post from BiotechBlog reader Viren Konde. Do you have a response to Viren’s post? If so, you may respond in the comments section below. The recent editorial on “Intellectual property and biotechnology innovation: To protect or not protect” by Dr Yali Friedman, Managing Editor of the Journal of Commercial Biotechnology was […]


Drug Patent Expirations in December 2009

Drug Patent Expirations for December 2009 Tradename Applicant Generic Name Patent Number Patent Expiration MIGRANAL Valeant dihydroergotamine mesylate 5,169,849 Dec 8, 2009 PHOTOFRIN Axcan Scandipharm porfimer sodium 5,145,863 Dec 15, 2009 XENICAL Hoffmann La Roche orlistat 4,598,089*PED Dec 18, 2009 CEDAX Sciele Pharma Inc ceftibuten dihydrate 4,812,561 Dec 20, 2009 OXILAN-300 Guerbet ioxilan 4,954,348 Dec […]


Is the practice of medicine impeding medical innovation?

At a recent event on the comparative advantages of small molecule vs. biologic drugs, several themes emerged which led me to re-examine the question of whether the practice of medicine is capable of keeping pace with medical innovation. As mentioned in a previous post, the majority of patients receiving the personalized medicine drug Herceptin had […]


Drug Patent Expirations in November 2009

Drug Patent Expirations for November 2009 Tradename Applicant Generic Name Patent Number Patent Expiration ACULAR LS Allergan ketorolac tromethamine 5,110,493*PED Nov 5, 2009 ACULAR Allergan ketorolac tromethamine 5,110,493*PED Nov 5, 2009 PREVPAC Takeda Pharms Na amoxicillin; clarithromycin; lansoprazole 4,628,098*PED Nov 10, 2009 PREVACID IV Takeda Pharms Na lansoprazole 4,628,098*PED Nov 10, 2009 ACEON Solvay Pharms […]


Biologic data exclusivity: The arguments for and against it

With the issue of data exclusivity for novel biologics re-emerging in the news, I’d like to present two arguments that will be published in the upcoming issue of the Journal of Commercial Biotechnology: Why data exclusivity is the new patent protection Peter J Pitts, Center for medicine in the public interest Follow-on biologic drug competition […]


Kyoto Prize Journalism Fellowship

I am honored to have been selected for the 2009 Kyoto Prize Journalism Fellowship, offered by Point Loma Nazarene University. This fellowship will allow me to attend the Kyoto Prize Ceremony, laureate lectures and workshops, and associated functions. The Kyoto Prize is one of the world’s most prestigious awards given to those who have made […]


Drug Patent Expirations in October 2009

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in October 2009 Tradename Applicant Generic Name Patent Number Patent Expiration BREATHTEK UBT FOR H-PYLORI Otsuka America urea, c-13 4,830,010 Oct 27, 2009 CEDAX Sciele Pharma Inc ceftibuten dihydrate 4,634,697 Oct 1, 2009 COLGATE TOTAL Colgate Palmolive sodium fluoride; triclosan 5,156,835 Oct 20, 2009 COVERA-HS Gd Searle Llc verapamil […]


Journal of Commercial Biotechnology — October 2009 issue now available

The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper: Volume 15, Issue 4 Editorial Intellectual property and biotechnology innovation: To protect or not protect? PDF Yali Friedman Commentary The correlation between medical tourism and biotechnology PDF David G Vequist […]